. 2022 Jun 14;114(8):1109–1116. doi: 10.1093/jnci/djac115

Table 3.

Association between rs2815063-A and CCD/CHF among survivors from the St. Jude Lifetime Cohort (SJLIFE) study and the Childhood Cancer Survivor Study (CCSS)^a

Cohorts	Analyses	Survivor cases		Survivor controls		Cumulative OR (95% CI)	P ^b
Cohorts	Analyses	No.	EAF	No.	EAF	Cumulative OR (95% CI)	P ^b
SJLIFE discovery cohort European ancestry	CTCAE grade ≥ 2	227	0.18	1643	0.12	1.57 (1.19 to 2.09)	.002
SJLIFE discovery cohort European ancestry	CTCAE grade ≥ 3	67	0.20	1643	0.12	1.80 (1.17 to 2.77)	.008
SJLIFE replication cohort African ancestry	CTCAE grade ≥ 2	43	0.51	258	0.49	1.16 (0.67 to 2.03)	.60
SJLIFE replication cohort African ancestry	CTCAE grade ≥ 3	20	0.50	258	0.49	1.10 (0.53 to 2.26)	.80
CCSS replication cohort	CTCAE grade ≥ 2	230	0.15	3790	0.13	1.21 (0.91 to 1.60)	.18
European ancestry	CTCAE grade ≥ 3	163	0.15	3790	0.13	1.40 (1.02 to 1.92)	.04

^{^a}

Covariates included sex, age at cancer diagnosis, age at last follow-up, cumulative anthracycline dose, average heart radiation dose, and the top 20 genotype-based principal components. CI = confidence interval; CTCAE = National Cancer Institute’s Common Terminology Criteria for Adverse Events; EAF = effect allele (A) frequency; OR = odds ratio.

P values were 2-sided based on cumulative logistic regression.